Synaffix

Synaffix, founded in 2010, is a biotechnology company with a clinical-stage platform that enables best-in-class antibody-drug conjugates (ADCs), bispecific antibodies, and other targeted therapies under a technology licensing business model. Committed to utilizing its site-specific conjugation ADC technology platform to generate highly competitive ADC candidates. Synaffix's business model is technology out-licensing.